Weight loss in advanced Alzheimer's disease, part I: Contributing factors and evaluation

Annals of Long-Term Care

Volumn 12, Issue 5, 2004, Pages 33-37

  White, Heidi K ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANTIBIOTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE INHIBITOR; DIGOXIN; GALANTAMINE; HALOPERIDOL; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PHENOTHIAZINE DERIVATIVE; SEDATIVE AGENT; THEOPHYLLINE;

AGED; ALZHEIMER DISEASE; ANAMNESIS; ANOREXIA; ATTENTION DEFICIT DISORDER; BEHAVIOR DISORDER; BODY WEIGHT DISORDER; CALORIC INTAKE; CYTOKINE PRODUCTION; DEPRESSION; DISEASE COURSE; DRUG INDUCED DISEASE; DYSPHAGIA; ENERGY EXPENDITURE; ESOPHAGITIS; EVALUATION; FEEDING BEHAVIOR; HUMAN; MALNUTRITION; MOTOR DYSFUNCTION; NAUSEA; NUTRITION; OROPHARYNX; PATHOPHYSIOLOGY; PHYSICAL EXAMINATION; REVIEW; RISK FACTOR; SMELLING DISORDER; TASTE DISORDER; TOOTH DISEASE; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

EID: 2942615189     PISSN: 15247929     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Omnibus Budget Reconciliation Act of 1987. Medicare and Medicaid requirements for long-term care facilities. 42 CFT. Part 483.
2. White H, Pieper C, Schmader K, Fillenbaum G. Weight change in Alzheimer's disease. J Am Geriatr Soc 1996;44:265-272.
3. Cronnin-Stubbs D, Beckett L, Scherr P, et al. Weight loss in people with Alzheimer's disease: A prospective population based analysis. BMJ 1997;314:178-179.
4. Du W, DiLuca C, Growdon JH. Weight loss in Alzheimer's disease. J Geriatr Psychiatry Neurol 1993;6:34-38.
5. Wolf-Klein GP, Silverstone FA, Levy AP. Nutritional patterns and weight change in Alzheimer patients. Int Psychogeritr 1992;4:103-118.
6. Burns A, Marsh A, Bender DA. Dietary intake and clinical, anthropometric and biochemical indices of malnutrition in elderly demented patients and nondemented subjects. Psychol Med 1989;19:383-391.
7. White H, Pieper C, Schmader K, Fillenbaum G. A longitudinal analysis of weight change in Alzheimer's disease. J Am Geriatr Soc 1997;45(4):531-532.
8. White H, Pieper C, Schmader K. The association of weight change in Alzheimer's disease with severity of disease and mortality: A longitudinal analysis. J Am Geriatr Soc 1998;46:1223-1227.
9. Keller HH. Weight gain impacts morbidity and mortality in institutionalized older persons. J Am Geriatr Soc 1995;43:165-169.
10. Volicer L, Seltzer B, Rheume Y, et al. Eating difficulties in patients with probable dementia of the Alzheimer type. J Geriatr Psychiatry Neurol 1989;2:188-195.
11. Blandford G, Watkins LB, Mulvihill M, Taylor B. Correlations of aversive feeding behaviors in dementia patients. J Am Geriatr Soc 1995;43:SA10, P4.
12. Morris CH, Hope RA, Fairburn CG. Eating habits in dementia. Br J Psych 1989;154:801-806.
13. van de Nes JA, Kamphorst W, Ravid R, Swaab DF. The distribution of Alz-50 immunoreactivity in the hypothalamus and adjoining areas of Alzheimer's disease patients. Brain 1993;116(Pt 1):103-115.
14. Swaab DF, Grundke-Iqbal I, Iqbal K, et al. and ubiquitin in the human hypothalamus in aging and Alzheimer's disease. Brain Res 1992;590:239-249.
15. Horner J, Alberts MJ, Dawson DV, Cook GM. Swallowing in Alzheimer's disease. Alzheimer Dis Assoc Disord 1994;8(3):177-189.
16. Chouinard J, Lavigne E, Villeneuve C. Weight loss, dysphagia, and outcome in advanced dementia. Dysphagia 1998;13(3):151-155.
17. Priefer BA, Robbins J. Eating changes in mild-stage Alzheimer's disease: A pilot study. Dysphagia 1997;12(4):212-221.
18. Schiffmon SS, Pasternak M. Decreased discrimination of food odors in the elderly. J Gerontol 1979;34:73-79.
19. Schiffman SS. Taste and smell losses in normal aging and disease. JAMA 1997;278:1357-1362.
20. Schiffman SS, Clark C, Warwick Z. Gustatory and olfactory dysfunction in dementia: Not specific to Alzheimer's disease. Neurobiol Aging 1990;11(6):597-600.
21. Serby M, Larson P, Kalkstein D. The nature and course of olfactory deficits in Alzheimer's disease. Am J Psychiatry 1991;148(3):357-360.
22. Koss E, Weiffenbach J, Haxby J, Friedland R. Olfactory detection and identification performance are dissociated in early Alzheimer's disease. Neurology 1988;38(8):1228-1232.
23. Murphy C, Gilmore MM, Seery CS, et al. Olfactory thresholds are associated with degree of dementia in Alzheimer's disease. Neurobiol Aging 1990;11:465-469.
24. Nordin S, Monsch AU, Murphy C. Unawareness of smell loss in normal aging and Alzheimer's disease: Discrepancy between self-reported and diagnosed smell sensitivity. J Gerontol B Psychol Sci Soc 1995;50B(4):P187-P192.
25. Price JL, Davis PB, Morris JC, White DL. The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease. Neurobiol Aging 1991;12:295-312.
26. Mesholam R, Moberg P, Mahr R, Doty R. Olfaction in neurodegenerative disease: A meta-analysis of olfactory function in Alzheimer's disease and Parkinson's disease. Arch Neurol 1998;55(1):84-90.
27. Inui A. Cancer anorexia-cachexia syndrome: Are neuropeptides the key? Cancer Res 1999;59:4493-4510.
28. Berry C, Clark AL. Catabolism in chronic heart failure. Eur Heart J 2000;21(7):521-532.
29. Griffin WS, Sheng JG, Roberts GW, Mrak RE. Interleukin-1 expression in different plaque types in Alzheimer's disease: Significance in plaque evolution. J Neuropathol Exp Neurol 1995;54:276-281.
30. Griffin WS, Sheng JG, Royston MC, et al. Glial-neuronal interactions in Alzheimer's disease: The potential role of a 'cytokine cycle' in disease progression. Brain Pathol 1998;8:65-72.
31. Ringheim GE, Szczepanik AM, Petko W, et al. Enhancement of beta-amyloid precursor protein transcription and expression by the soluble interleukin-6 receptor/interleukin-6 complex. Brain Res Mol Brain Res 1998;55:35-44.
32. Hull M, Berger M, Volk B, Bauer J. Occurrence of interleukin-6 in cortical plaques of Alzheimer's disease patients may precede transformation of diffuse into neuritic plaques. Ann N Y Acad Sci 1996;777:205-212.
33. Donaldson KE, Carpenter WH, Toth MJ; et al. No evidence for a higher resting metabolic rate in non-institutionalized Alzheimer's patients. J Am Geriatr Soc 1996;44:1232-1234.
34. Niskanen L, Piirainen M, Koljonen M, Uusitupa M. Resting energy expenditure in relation to energy intake in patients with Alzheimer's disease, multiinfarct dementia and in control women. Age Ageing 1993;22:132-137.
35. Poehlman ET, Toth MJ, Goran MI, et al. Daily energy expenditure in free-living non-institutionalized Alzheimer's patients: A doubly labeled water study. Neurology 1997;48:997-1002.
36. Gillette-Guyonnet S, Nourhashemi F, Andrieu S, et al. Weight loss in Alzheimer's disease. Am J Clin Nutr 2000;71(suppl):637S-642S.
37. White HK, McConnell ES, Bales CW, Kuchibbahtia M. A 6-month observational study of the relationship between weight loss and behavioral symptoms in institutionalized AD subjects. J Am Med Dir Assoc. In press.
38. White HK. Dementia. In: Bales CW, Ritchie SC, eds. Handbook of Clinical Nutrition and Aging. Totowa, NJ: Humana Press; 2004:349-365.
39. Council for Nutritional Clinical Strategies in Long-Term Care. Clinical Guide to Prevent and Manage Malnutrition in Long-Term Care. Newtown Square, PA: Programs in Medicine; 2000. Available at: http://www.ltcnutrition.org. Accessed January 14, 2004.
40. Wilson MG, Morley JE. Nutritional assessment and support in chronic disease management. In: Bales CW, Ritchie SC, eds. Handbook of Clinical Nutrition and Aging. Totowa, NJ: Humana Press; 2004:77-101.
41. Abbasi AA, Rudman D. Observations on the prevalence of protein-calorie undernutrition in VA nursing homes. J Am Geriatr Soc 1993;41(2):117-121.
42. Sokoloff LG, Pavlakovic R. Neuroleptic induced dysphagia. Dysphagia 1997;12:177-179.
43. Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 1998;50:136-145.
44. Rosler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomized controlled trial. BMJ 1999;318(7184):633-638.
45. Raskind MA, Peskind ER, Wessel T, et al. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 2000;54(12):2261-2268.
46. Langmore SE, Terpenning MS, Schork A, et al. Predictors of aspiration pneumonia: How important is dysphagia? Dysphagia 1998;13:69-81.ion. J Psychiatry Neurosci 2000;25(2):61-166.
47. Langmore SE, Terpenning MS, Schork A, et al. Predictors of aspiration pneumonia: How important is dysphagia? Dysphagia 1998;13:69-81.ion. J Psychiatry Neurosci 2000;25(2):161-166.